Stock comparison
Haemonetics
Summit Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.43B
Sector
Healthcare
SMMT
Summit Therapeutics
Market cap
$13.08B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | SMMT | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 14F | HAE |
| Benjamin Graham | 85A | 54D | HAE |
| Philip Fisher | 60C | 46D | HAE |
| Peter Lynch | 54C | 64C | SMMT |
| Joel Greenblatt | 31F | 0F | HAE |
| Charlie Munger | 54D | 20F | HAE |
| Terry Smith | 55D | 19F | HAE |
Side-by-side metrics
| Metric | HAE | SMMT |
|---|---|---|
| Market cap | $2.43B | $13.08B |
| P/E (TTM) | 24.8x | - |
| EV/EBIT | 14.1x | - |
| ROIC (TTM) | 8.37% | -2.48% |
| Gross margin | 55.74% | 0.0% |
| Net margin | 7.29% | 0.0% |
| Revenue CAGR 5y | 7.65% | - |
| EPS CAGR 5y | 24.62% | 39.68% |
| Debt / Equity | 1.5x | 0.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- ROIC (TTM)8.37%vs -2.48%+103%
- Gross margin55.74%vs 0.0%+100%
- Net margin7.29%vs 0.0%+100%
SMMT leads on
- EV/EBIT-vs 14.1x+184%
- P/E (TTM)-vs 24.8x+150%
- Debt / Equity0.0xvs 1.5x+98%
- Market cap$13.08Bvs $2.43B+81%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.